Peter G. Traber

Peter G. Traber is a declared insider at 3 companies (senior executive); the most frequent names are Cartesian Therapeutics, Inc., Galectin Therapeutics Inc and Lisata Therapeutics, Inc. We count 47 filings; the first trade dates from 13 February 2009 and the latest from 25 September 2023.

Both buying and selling appear: 18 purchases worth €356k, against 10 sales worth €1.0M. On balance, insiders were net sellers of €674k. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Outside the open market, there are 17 share grants and 2 option exercises. 2023 to date brings no purchases and 5 sales.

A typical purchase (the median) is worth €6,675. Clusters matter here: 3 out of 6 purchases overlapped with buying by a colleague within 30 days. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. Ninety days after publication, 18 purchases show a median change of -0.2%, with the price up in 50% of them. This is a record of the past, not a forecast.

Most recently, on 26 September 2023, the filings show an open-market sale worth €706 in Cartesian Therapeutics, Inc. The most recent open-market purchase was published on 27 May 2021, 1,992 days ago. Typically, a trade is published a median of 2 days after it takes place. US insiders must file a Form 4 within two business days of a trade. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.